Update on the Management of COPD

Connecticut Medicine

Volumn 73, Issue 4, 2009, Pages 217-221

  Colby, Jennifer ^a   Goldman, Monica ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; INFLUENZA VACCINE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; DISEASE MANAGEMENT; DRUG COMBINATION; HUMAN;

ADRENERGIC BETA-AGONISTS; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CLINICAL PROTOCOLS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; INFLUENZA VACCINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 66349128028     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mannino DM, Buist AS: Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007; 370:765- 73.
2. National Institutes of Health: National Heart, Lung, and Blood Institute: Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung and Blood Diseases. (Available at: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf, accessed 10/28/08.)
3. Lopez AD, Shibuya K, Rao C, et al: Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27(2):397-412.
4. World Health Organization: Chronic Respiratory Diseases. (Available at: http://www.who.int/respiratory/copd/burden/en/index.html,accessed 11/4/08.)
5. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064):1498-504.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategyforthediagnosis,management,and prevention of chronic obstructive pulmonary disease, updated 2007,Executive Summary,pp.l-32.(Availableat:http:// www.goldcopd.com/Guidelineitem. asp?ll=2&12=l&infld=996, accessed 10/20/08.)
7. Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364(9435):709- 21.
8. Augustí AG: Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:367-70.
9. Gross NJ: Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2001; 7:84-92.
10. Schols AM: Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000; 6:110-5.
11. National Institute for Clinical Excellence (NICE).Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59(Suppl. 1): 1-232.
12. Celli BR, MacNee W, Agusti A, et al for the ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J2004; 23:932-46.
13. Micromedex® Healthcare Series. (Version 5.1) [Intranet]. Greenwood Village, CO : Thomson Healthcare.
14. 2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58:580-4.
15. Vincken W, Van Noord JA, Greefhorst APM, et al: Improved health outcomes in patients with COPD during one-year's treatment with tiotropium. Eur Respir J 2002; 19:209-16.
16. O'Donnell DE, FlügeT, Gerken F, et al: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J2004; 23:832-40.
17. Man WD, Mustfa N, Nikoletou D, et al: Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59:471-6.
18. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105(5):1411-9.
19. Gartlehner G, Hansen RA, Carson SS, et al: Efficacy and safety of inhaled corticosteroids in patients with COPD: A systematic review and meta-analysis of health outcomes.AnnFam Med 2006; 4(3):253-62.
20. The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26): 1902-9.
21. Jones PW, Willits LR, Burge PS, et al: On behalf of the inhaled steroids in obstructive lung disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2002; 21:68-73.
22. Decramer M, Lacquef LM, Fagard R, et al: Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150:11-16.
23. Davies L, Angus RM, Calverley PMA: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Lancet 1999; 354(9177):456-60.
24. Szafranski W, Cukier A, Ramirez A, et al: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
25. Calverley PMA, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775-89.
26. Kardos P, Wencker M, Glaab T, Vogelmeier C: Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(2):144-9.
27. Gilbert DN, Moellerine RC, Eliopoulos GM, et al: editors: Tie Sanford Guide to Antimicrobial Therapy 2008. Virginia: Antimicrobial Therapy, Inc.; 2008.
28. Kuti J: Center for Anti-Infective Research and Development, personal communication.
29. Wongsurakiat P, Maranetra KN, Wasi C, et al: Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: A randomized controlled study. Chest 2004; 125(6):2011-20.
30. Department of Health and Human Services, Centers for Disease Control: Adult Immunization Schedule, MMWR Quick Guide. (Available at: http://www.cdc.gov/mmwr/pdf/wk/mm5641-Immunization.pdf, accessed 11/7/08.)
31. Nichol KL, Baken L, Nelson A, et al: Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130(5): 397-403.
32. Jackson LA, Keuzil KM, Yu O, et al: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348(18): 1747-55.
33. Murphy K, Noonan M, Silkoff PE, Uryniak T: A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler. Clin Ther 2007; 29(6): 1013-26.